Sorafenib, PERK, or eIF2α kinase inhibition is known to be the most critical kinase in promoting the development of SGs.The PERK-eIF2α-SG pathway has been identified as the primary mechanism of sorafenib resistance in hepatocellular cancer. This evidence concerns the gene EIF2AK3 and hepatocellular carcinoma.